Elanco Animal Health Hits New 52-Week High of $20.91

Elanco Animal Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 20.91 on October 1, 2025. This achievement underscores the company's performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of approximately USD 9,464 million.
Over the past year, Elanco has demonstrated a solid performance with a gain of 14.04%, although it slightly trails the S&P 500's performance of 16.09%. The company's price-to-earnings (P/E) ratio stands at 14.00, indicating its valuation relative to earnings. Additionally, Elanco maintains a debt-to-equity ratio of 0.54, reflecting a moderate level of leverage.

Despite not offering a dividend yield, the company has achieved a return on equity of 7.26%, showcasing its ability to generate profits from shareholders' equity. The stock's previous 52-week low was recorded at USD 8.02, highlighting the significant upward movement in its price. This recent high marks a notable point in Elanco's financial journey within the competitive landscape of the pharmaceuticals and biotechnology industry.